Physician profile
Pablo E Perez
NPI 1942218086
$15,738.08
in general payments reported to CMS, 2019-2025
61 companies · $4,628 in 2025
The $4,628 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,916 · 2020: $2,116 · 2021: $1,822 · 2022: $1,854 · 2023: $1,545 · 2024: $1,858 · 2025: $4,628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,546 · Consulting Fee: $2,485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,546.14 |
| Consulting Fee | $2,485.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,292.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $2,469.30 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,427.01 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $1,074.47 | 2021-2025 | |
| Amgen INC. | $889.62 | 2019-2025 | Evenity, Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $613.19 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $570.61 | 2021-2025 | |
| Axsome Therapeutics, INC. | $373.38 | 2023-2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $361.56 | 2023-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $342.60 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $339.45 | 2019-2022 | |
| Abbott Laboratories | $330.57 | 2020-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $326.80 | 2020-2024 | Shingrix, Trelegy Ellipta |
| Corcept Therapeutics | $270.66 | 2021-2024 | Korlym |
| Allergan, INC. | $256.32 | 2019-2020 |
Show all 56 companies
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pablo Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.